This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Earnings Preview: J&J 1Q To Focus On Newest Drugs

By LINDA A. JOHNSON

TRENTON, N.J. (AP) â¿¿ Johnson & Johnson will highlight the recent approval of its first drug in the huge diabetes market, plus progress toward getting two other drugs approved, when it reports first-quarter results before the stock market opens Tuesday.

WHAT TO WATCH FOR: The world's biggest maker of health care products will focus on the March 29 U.S. approval of Invokana, known chemically as canagliflozin. The daily pill is the first drug in a new class of Type 2 diabetes medicines that work by increasing how much sugar is excreted via urine.

J&J's first entry in the multibillion-dollar medicine market fueled by the global diabetes epidemic, Invokana will complement its OneTouch and Vibe lines of all manner of diabetes devices. Executives should discuss plans for launching Invokana, including having sales reps for those diabetes devices promote it. It's awaiting approval in some other countries.

Chief Financial Officer Dominic Caruso will update J&J's 2013 profit forecast. He will note a charge of about 4 cents per share due to Venezuela's currency devaluation and likely discuss exchange rate effects.

J&J will note prostate cancer drug Zytiga got European Union approval in January for use earlier in treatment â¿¿ before chemotherapy.

J&J, based in New Brunswick, N.J., just applied for Food and Drug Administration approval of simprevir, its second drug for hepatitis C. That's another disease with a fast-growing market, as baby boomers infected decades ago finally get diagnosed with the silent liver-destroying disorder.

This week, the FDA granted a third breakthrough therapy designation for a cancer drug still in testing, ibrutinib. That's meant to speed up late-phase testing and review of the drug. J&J plans this year to seek approval for the drug as a treatment for mantle cell lymphoma.

Those positives are offset by a surge of litigation over allegedly faulty products, plus the company's continuing struggle to end an eye-popping streak of about three dozen product recalls. Most were nonprescription medicines, including Tylenol and Motrin. Reasons range from nauseating packaging smells to tiny glass and metal shards in liquid medicines. Some products are still off store shelves after three years, reducing revenue. The company is rebuilding one factory from the ground up and making other manufacturing improvements under an agreement with the FDA, hiking the tab.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,461.32 -153.49 -0.92%
S&P 500 1,927.11 -14.17 -0.73%
NASDAQ 4,382.8470 -36.6310 -0.83%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs